Skip to main content

Supplementary Table S4 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Publication ,  Other
Halabi, S; Guo, S; Park, JJ; Nanus, DM; George, DJ; Antonarakis, ES; Danila, DC; Szmulewitz, RZ; McDonnell, DP; Norris, JD; Lu, C; Luo, J ...
March 15, 2024

<p>Hazard Ratio of PFS by baseline HOXB13 status, (CellSearch) CTC, and JHU AR-V7</p>

Duke Scholars

DOI

Publication Date

March 15, 2024
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Halabi, S., Guo, S., Park, J. J., Nanus, D. M., George, D. J., Antonarakis, E. S., … Armstrong, A. J. (2024). Supplementary Table S4 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. https://doi.org/10.1158/1078-0432.25415364
Halabi, Susan, Siyuan Guo, Joseph J. Park, David M. Nanus, Daniel J. George, Emmanuel S. Antonarakis, Daniel Costin Danila, et al. “Supplementary Table S4 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide,” March 15, 2024. https://doi.org/10.1158/1078-0432.25415364.
Halabi S, Guo S, Park JJ, Nanus DM, George DJ, Antonarakis ES, Danila DC, Szmulewitz RZ, McDonnell DP, Norris JD, Lu C, Luo J, Armstrong AJ. Supplementary Table S4 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. 2024.

DOI

Publication Date

March 15, 2024